The impact and medical reality of Ozempic: What you need to know
In the current health and wellness landscape, Ozempic has gained unprecedented notoriety. This drug, whose active ingredient is semaglutide, has positioned itself as a key tool in the treatment of type 2 diabetes, although its use has expanded in public discourse due to its weight loss effects. From Alofoke Deportes, we analyze the importance of understanding this medication from a rigorous and supervised medical perspective.
Developed by the Danish pharmaceutical company Novo Nordisk, founded in 1923, Ozempic works as a subcutaneous injectable for weekly application. Its main mechanism consists of stimulating insulin release in the presence of high glucose levels and slowing gastric emptying, which generates a greater feeling of satiety in the patient.
Key differences: Ozempic vs. Wegovy
It is essential to clarify that, although semaglutide is the central component of both, Ozempic is specifically designed for the management of type 2 diabetes. For the clinical treatment of obesity, the pharmaceutical industry developed Wegovy, which has the relevant authorizations for that purpose. The confusion between the two has led many users to seek the drug as a quick fix, ignoring the need for a professional medical prescription.
Ozempic is not a miracle drug or a product intended simply for weight loss. It is a pharmacological treatment with proven benefits for certain people and potential adverse effects that justify its use under medical supervision.
Risks, side effects and benefits
Like any high-potency drug, its administration is not without risks. The most common side effects reported include:
- Persistent nausea and vomiting.
- Diarrhea or constipation.
- Frequent abdominal pain.
- Possible gastrointestinal and renal complications.
- Risk of pancreatitis or gallbladder disorders.
Likewise, there are critical contraindications. The medication should not be used by people with a personal or family history of medullary thyroid carcinoma, nor by those suffering from multiple endocrine neoplasia syndrome type 2.
On the other hand, science has supported significant cardiovascular benefits. In specific patients with type 2 diabetes and heart disease, a relevant reduction in the risk of serious cardiovascular events has been observed, which highlights the importance of its use under clinical medical criteria and not aesthetic ones.
In conclusion, the key to the use of semaglutide lies in patient education and strict professional monitoring, preventing the drug’s popularity from overshadowing the responsibility that its administration entails.
